Disc Medicine Inc. (IRON) Stock Forecast & Price Target
Disc Medicine Inc. · NASDAQ
$74.55-0.06 (-0.08%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 8 firms covering Disc Medicine Inc, 8 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $79.00 to $125.00, a moderate spread. The average target of $97.25 sits 30% above the current $74.55. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-1.86 next quarter toward $-7.59 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS8 ratings
Strong Buy
Strong Buy113%
Buy788%
Hold00%
Sell00%
Strong Sell00%
Based on 8 analysts giving stock ratings to Disc Medicine Inc.
As of Jul, 8 of 8 firms rate IRON a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IRON EPS & revenue forecast
EPS · NEXT QUARTER
$-1.86
Range $-2.14 – $-1.62 · 9 analysts · +5% YoY
Next period, 9 analysts expect Disc Medicine Inc. to earn $-1.86 a share (range $-2.14 – $-1.62), versus $-1.77 a year earlier. Full-year consensus is $-7.16, growing to $-7.59 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 9 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $32.2M next year.
Top analysts covering Disc Medicine Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRON.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Buy
$85.00+14.0% to target
Overall win rate
61%
+ Follow
#2
David Nierengarten
Wedbush · Rank #115
Buy
$88.00+18.0% to target
Overall win rate
41%
+ Follow
#3
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$125.00+67.7% to target
Overall win rate
38%
+ Follow
#4
Greg Harrison
Scotiabank · Rank #177
Buy
$75.00+0.6% to target
Overall win rate
38%
+ Follow
#5
Douglas Tsao
HC Wainwright & Co. · Rank #212
Buy
No targeton IRON
Overall win rate
35%
+ Follow
IRON stock forecast FAQ
What is IRON's average 12-month price target?+
The 8 analysts with a live target average $97.25 for Disc Medicine Inc. over the next 12 months, ranging from a $125.00 high to a $79.00 low.
Is IRON stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 8 analyst ratings, 8 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IRON?+
The Street-high target is $125.00 (Cantor Fitzgerald), and the Street-low is $79.00 (Wells Fargo). The average of all 8 active targets is $97.25.
How many Wall Street analysts cover IRON?+
8 analysts have an active rating on Disc Medicine Inc., and 8 firms carry a live 12-month price target.
Who is the most accurate analyst covering IRON?+
Among analysts who currently cover IRON, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Buy with a $85.00 target.
What is Disc Medicine Inc.'s projected EPS for next quarter?+
The consensus estimate is $-1.86 per share (range $-2.14 – $-1.62) across 9 analysts. Full-year EPS is projected at $-7.16, rising to $-7.59 the following year.
How much revenue is Disc Medicine Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $32.2M next year.
Have analysts been upgrading or downgrading IRON lately?+
As of Jul, 8 of 8 firms rate IRON a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRON calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
